- Details
- Maria De Santis discusses managing frail patients with metastatic hormone-sensitive prostate cancer. Dr. De Santis explains the importance of defining frailty, which involves five key factors: unintended weight loss, weakness, low physical activity, difficulty lifting objects, and mobility issues. She highlights the necessity of evaluating frailty using tools like the G8 screening and emphasizes t...
|
- Details
- Oliver Sartor discusses his approach to treating low-volume metastatic prostate. Dr. Sartor emphasizes the importance of molecular imaging, particularly PSMA PET, to define low-volume and oligometastatic disease accurately. He advocates for a "total therapy" approach, combining androgen deprivation, novel hormones, and targeted radiation, including SBRT for metastatic sites and pelvic radiation. D...
|
- Details
- Michael Morris discusses optimal imaging standards for metastatic hormone-sensitive prostate cancer. He explains that conventional imaging methods like PSA tracking are insufficient for monitoring disease progression in the era of advanced androgen receptor signaling inhibitors (ARSIs). Dr. Morris emphasizes the need for regular imaging, recommending scans every six to twelve months to detect radi...
|
- Details
- Zach Klaassen discusses the EvoPAR-Prostate 01 trial with Neeraj Agarwal. The trial examines a new PARP inhibitor combined with ARPI in metastatic hormone-sensitive prostate cancer, both in biomarker-positive and -negative populations. Dr. Agarwal explains the rationale based on preclinical data and previous trials like PROpel and TALAPRO-2, showing efficacy in HRR mutation-positive patients and p...
|
- Details
- Alicia Morgans speaks with Joaquin Mateo about his presentation on PARP inhibitors. Dr. Mateo discusses the role of PARP inhibitors in treating metastatic castration-resistant prostate cancer (mCRPC) with BRCA1 or BRCA2 mutations, noting the poor prognosis associated with these mutations but highlighting the effectiveness of PARP inhibitors like olaparib and rucaparib. He explains the differences...
|
- Details
- Andrea Miyahira discusses a study on noninvasive detection of neuroendocrine prostate cancer with Himisha Beltran and Francesca Demichelis. Their collaborative paper, published in Cancer Discovery, introduces a targeted cell-free DNA methylation panel called NEMO (Neuroendocrine Monitoring). This panel aims to distinguish neuroendocrine prostate cancer from adenocarcinoma using DNA methylation pat...
|
- Details
- Zach Klaassen speaks with Todd Morgan about innovative approaches in the management of prostate cancer post-prostatectomy. Dr. Morgan presents compelling new data on the prostate AI test, highlighting its use in identifying biochemical recurrence after prostatectomy. This AI model, validated with data from key trials, not only distinguishes patients based on the aggressiveness of their disease but...
|
- Details
- Alicia Morgans engages with Noel Clarke on the critical issue of bone health in prostate cancer patients, particularly those undergoing androgen deprivation therapy (ADT). Professor Clarke shares findings from the STAMPEDE trial and other studies that highlight the high fracture rates in these patients. He criticizes the reliability of the FRAX scoring system, which was originally developed for a...
|
- Details
- Alicia Morgans interviews Thomas Zilli about the PEACE V study. The study, termed the STORM trial, investigates treatment strategies for patients with oligorecurrent prostate cancer, comparing focalized SBRT, comprehensive irradiation, and salvage lymph node dissection combined with six months of ADT. Aimed at determining the best approach for these patients, the trial specifically looks at metast...
|
- Details
- Alicia Morgans speaks with Bertrand Tombal about his presentation at EAU 2024, focusing on the European subset of the ARASENS trial. Professor Tombal discusses the importance of the data from this trial, which assessed the efficacy of adding darolutamide to standard treatment for metastatic hormone-naive prostate cancer. The trial confirmed that this combination significantly reduced mortality ris...
|
